Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditi...

Aduro Clean Technologies Reports Third Quarter Fiscal 2025 Results

LONDON, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or t...

Aduro Clean Technologies Offers Value Amid Stock Chaos

The markets are up. The markets are down. Good companies are losing value due to fears of potenti...

Transformational Event Upcoming for LEEF Brands

LEEF Brands Inc. (CSE: LEEF) (OTCQB: LEEEF), a California-based cannabis extraction company, is p...

Aduro CEO Interviewed on Nasdaq Amplify Issuer Spotlight

Aduro Clean Technologies, Inc. (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5) CEO Ofer Vicus was featured o...

From $1 to $8? Why Analyst Experts Are Bullish on Cardiol

Sometimes stock market performance doesn’t line up with the fundamentals of a public company, lea...